CA1090704A - Prevention de l'infarctus du myocarde - Google Patents
Prevention de l'infarctus du myocardeInfo
- Publication number
- CA1090704A CA1090704A CA277,488A CA277488A CA1090704A CA 1090704 A CA1090704 A CA 1090704A CA 277488 A CA277488 A CA 277488A CA 1090704 A CA1090704 A CA 1090704A
- Authority
- CA
- Canada
- Prior art keywords
- myocardial infarction
- pyridyl
- composition
- beta
- myocardial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 16
- 230000002265 prevention Effects 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000001802 infusion Methods 0.000 claims abstract description 11
- 208000001778 Coronary Occlusion Diseases 0.000 claims abstract description 9
- 206010011086 Coronary artery occlusion Diseases 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 5
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229960001392 betahistine hydrochloride Drugs 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004536 betahistine Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 230000002107 myocardial effect Effects 0.000 abstract description 4
- 206010061216 Infarction Diseases 0.000 description 10
- 230000007574 infarction Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- XVDFMHARQUBJRE-UHFFFAOYSA-N hydron;n-methyl-2-pyridin-2-ylethanamine;dichloride Chemical compound Cl.Cl.CNCCC1=CC=CC=N1 XVDFMHARQUBJRE-UHFFFAOYSA-N 0.000 description 9
- -1 ~umarate Chemical compound 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- QLSJOGIENLKPTF-WLHGVMLRSA-N (e)-but-2-enedioic acid;pyridine Chemical compound C1=CC=NC=C1.OC(=O)\C=C\C(O)=O QLSJOGIENLKPTF-WLHGVMLRSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- SHYFYRQVXCELNA-UHFFFAOYSA-N 2-ethylpyridine dihydrochloride Chemical compound Cl.Cl.CCC1=CC=CC=N1 SHYFYRQVXCELNA-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- NQMNIZQHNXIHJI-UHFFFAOYSA-N n-methyl-1-pyridin-2-ylpropan-2-amine;hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=N1 NQMNIZQHNXIHJI-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA277,488A CA1090704A (fr) | 1977-05-03 | 1977-05-03 | Prevention de l'infarctus du myocarde |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA277,488A CA1090704A (fr) | 1977-05-03 | 1977-05-03 | Prevention de l'infarctus du myocarde |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1090704A true CA1090704A (fr) | 1980-12-02 |
Family
ID=4108555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA277,488A Expired CA1090704A (fr) | 1977-05-03 | 1977-05-03 | Prevention de l'infarctus du myocarde |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1090704A (fr) |
-
1977
- 1977-05-03 CA CA277,488A patent/CA1090704A/fr not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1202240A (fr) | Medicament transdermique a base d'acide 2-(4-isobutylphenyl)-propionique; methode de preparation | |
| DE69940673D1 (de) | Orales system zur verabreichung von gepulsten dosen eines arzneistoffs | |
| WO1992022290A1 (fr) | Emploi du blocage par spin pour le traitement de maladies associees a l'oxydation des lipides et des proteines | |
| Kuttler | Pharmacotherapeutics of drugs used in treatment of anaplasmosis and babesiosis | |
| DE69634269D1 (de) | Verfahren zum modulieren der mikrozirkulation | |
| JPH0584286B2 (fr) | ||
| Heyl et al. | Effects of carbamates on whole blood cholinesterase activity: chemical protection against soman | |
| US20120064152A1 (en) | Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same | |
| JPH0647545B2 (ja) | 医薬用組成物 | |
| McCune | The delayed appearance of isoniazid antagonism by pyridoxine in vivo | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| US5550153A (en) | Method for treating heartworm-infected canines | |
| Sheppeard et al. | Osmic acid versus yttrium-90 in rheumatoid synovitis of the knee | |
| US4543359A (en) | Treating cardiac arrhythmias with dantrolene sodium | |
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| US4159332A (en) | Prevention of or reduction in severity of myocardial infarction | |
| US4730007A (en) | Novel analgesic compositions | |
| CA2154455A1 (fr) | Composition analgesique | |
| Culp et al. | Effects of anti-inflammatory drugs in shock caused by injection of living E. coli cells | |
| US4575506A (en) | Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics | |
| JPS60112715A (ja) | 中枢性鎮痛剤の耐薬性発現抑制剤 | |
| Kreutler et al. | Normal and promoted GI absorption of water-soluble substances III: Absorption of antibiotics from stomach and intestine of the rat | |
| Natelson et al. | A role for environmental factors in the production of digitalis toxicity | |
| JPS6342603B2 (fr) | ||
| JPH03505447A (ja) | アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |